[CAS NO. 205309-81-5] DL-TBOA
PRODUCTS SPECIFICATIONS [205309-81-5]
DESCRIPTION [205309-81-5]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 239.22 |
| Molecular Formula | C11H13NO5 |
| SMILES | OC([C@@H](N)[C@@H](C(O)=O)OCC1=CC=CC=C1)=O.[Relative stereochemistry] |
Summary
DL-TBOA is a potent non-transportable inhibitor of excitatory amino acid transporters with IC 50 s of 70 μM, 6 μM and 6 μM for excitatory amino acid transporter-1 (EAAT1) , EAAT2 and EAAT3 , respectively. DL-TBOA inhibits the uptake of [ 14 C]glutamate in COS-1 cells expressing the human EAAT1 and EAAT2 with K i valuesof 42 μM and 5.7 μM, respectively. DL-TBOA blocks EAAT4 and EAAT5 in a competitive manner with K i values of 4.4 μM and 3.2 μM, respectively [1] [2] [3] .
IC50 & Target
In Vitro
DL-TBOA (70-350 μM; 48 hours; HCT116 and LoVo cell lines) treatment concentration-dependently enhances SN38-induced loss of viability. DL-TBOA reversed Oxaliplatin-induced loss of viability
[4]
.
DL-TBOA (350 μM; 24 hours; HCT116 and LoVo cell lines) treatment decreases p53 induction by SN38 and oxaliplatin
[4]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [4]
| Cell Line: | HCT116 and LoVo cell lines |
| Concentration: | 70 μM, 350 μM |
| Incubation Time: | 48 hours |
| Result: | Enhanced SN38-induced, and counteracted Oxaliplatin-induced, cell death. |
Cell Viability Assay [4]
| Cell Line: | HCT116 and LoVo cell lines |
| Concentration: | 350 μM |
| Incubation Time: | 24 hours |
| Result: | p53 induction by SN38 and oxaliplatin was decreased. |
In Vivo
DL-TBOA (10 nmol; i.c.v.) to morphine-dependent rats significantly facilitates the expression of naloxone-precipitated somatic signs and conditioned place aversion
[5]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male Sprague-Dawley rats (180-250 g) [5] |
| Dosage: | 1 nmol, 3 nmol, 10 nmol |
| Administration: | Intracerebroventricularly injection (i.c.v.) |
| Result: | Dose dependently facilitated various somatic signs induced by Naloxone (0.1 mg/kg)-precipitated morphine withdrawal. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 200 mg/mL ( 836.05 mM ; Need ultrasonic)
H 2 O : 5 mg/mL ( 20.90 mM ; ultrasonic and warming and heat to 60°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.1803 mL | 20.9013 mL | 41.8025 mL |
| 5 mM | 0.8361 mL | 4.1803 mL | 8.3605 mL |
| 10 mM | 0.4180 mL | 2.0901 mL | 4.1803 mL |
References
- [1] Shimamoto K, et al. DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol Pharmacol. 1998 Feb;53(2):195-201.
- [2] Jabaudon D, et al. Inhibition of uptake unmasks rapid extracellular turnover of glutamate of nonvesicular origin. Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8733-8.
- [3] Shigeri Y, et al. Effects of threo-beta-hydroxyaspartate derivatives on excitatory amino acid transporters (EAAT4 and EAAT5). J Neurochem. 2001 Oct;79(2):297-302.
- [4] Pedraz-Cuesta E, et al. The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells. BMC Cancer. 2015 May 16;15:411.